GeoVax Labs, Inc. (Nasdaq: GOVX) has drawn attention to the alignment between its recently presented Phase 2 clinical data for GEO-CM04S1 and the new Infectious Diseases Society of America (IDSA) guidelines that prioritize vaccination for immunocompromised patients. The IDSA guidance, issued October 17, 2025, concluded that existing COVID-19 vaccines provide only moderate and short-lived protection for immunocompromised patients, with effectiveness against hospitalization ranging from 33% to 56% and waning within two months. The panel called for new vaccine strategies tailored to vulnerable populations, including cancer patients, transplant recipients, and individuals receiving immunosuppressive therapies.
At the World Vaccine Congress Europe 2025 in Amsterdam, GeoVax presented interim data from ongoing Phase 2 studies of GEO-CM04S1, the company’s multi-antigen, MVA-based COVID-19 vaccine designed for immunocompromised populations. Key findings included robust T-cell responses to both Spike and Nucleocapsid antigens, exceeding responses seen with mRNA boosters; broad, cross-variant immunity, including activity against Omicron subvariants; and a favorable safety profile, with only mild-to-moderate adverse events such as injection site reactions, fatigue, and myalgia, and no vaccine-related serious adverse events reported. In patients with hematologic malignancies post-transplant or CAR-T therapy, breakthrough infections were mild-to-moderate, underscoring the vaccine’s protective potential.
David A. Dodd, Chairman & CEO of GeoVax, stated, “Immunocompromised Americans are not a niche. They are cancer patients, transplant recipients, people with autoimmune disease, and those living with HIV - one in eight adults. Yet mainstream vaccine approaches, heavily centered on mRNA, continue to leave them without durable protection. The new IDSA guidelines reinforce the urgent need for alternatives like GeoVax’s GEO-CM04S1.” GEO-CM04S1 is a multi-antigen, Modified Vaccinia Ankara (MVA)-based vaccine designed to elicit both antibody and T-cell immune responses, which is particularly important for patients who often fail to mount sufficient antibody responses with current mRNA vaccines.
The vaccine’s key features include multi-antigen breadth (Spike + Nucleocapsid proteins) to provide broader immunologic coverage and remain relevant as the virus evolves, and durable cellular immunity critical where antibody responses are weak. Ongoing trials include Phase 2 studies as a primary vaccine for immunocompromised individuals and as a booster for patients with chronic lymphocytic leukemia (CLL). Interim results consistently demonstrate that GEO-CM04S1 can generate broader, more durable protection than mRNA vaccines while maintaining a strong safety profile.
The IDSA guidelines and GeoVax’s clinical data together underscore the limitations of relying on a single vaccine platform. Dodd added, “Protecting the over 40 million immunocompromised Americans is both a moral imperative and a national security necessity. With positive clinical data and alignment with IDSA guidance, GeoVax is delivering a differentiated vaccine platform designed to serve those who need it most.” For more information, visit GeoVax's website.
